REFERENCES
- Rothenberg M, Meropol N, Poplin E, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801–3807.
- Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: 1501-1518.
- Advanced colorectal cancer meta - analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903.
- Armand JP, Ducreux M, Mahjoubi M et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995; 31 A: 1283-1287.
- Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905–914.
- Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multi-centre randomized trial. Lancet 2000; 355: 1041–1047.
- Abigerges D, Armand JP, Chabot CC, et al. Irinotecan article (CPT-11) high-dose escalation using intensive high-dose lop-eramid to control diarrhea. J Natl Cancer Inst 1994; 11: 196–197.
- Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluo-rouracil (5-FU). Eur J Cancer 1999; 35: 54–59.
- Sargent D, Niedzwiecki D, O'Connell M, et al. Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144–145.
- Elfring G, Emanuel D, Rostagi R, et al. Patterns of use and mortality in community oncology practice setting among patients receiving first-line weekly bolus irinotecan/5-fluo-rouracil/leucovorin (IFL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21: 133a, (abstr 530).
- Goldberg RM, Morton RF, Sargent DJ, et al. N9741 oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (FU)/leucovorin (LV) or oxal + CPT-11in advanced colorectal cancer (CRC). Initial toxicity and response data from GI Intergroup study. Proc Am Soc Clin Oncol 2002; 21: 128a, (abstr 511).
- Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20: 124a, (abstr 494).